Research Reports

Key takeaways

Scholar Rock resubmitted its BLA for apitegromab to the FDA on March 31, 2026, for treating spinal muscular atrophy in children and adults.

The company anticipates FDA acceptance within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026.

The resubmission includes Catalent Indiana LLC and a second U.S.-based fill-finish facility, following alignment with FDA guidance from a March 3, 2026 Type C meeting.

The EMA review of the Marketing Authorisation Application for apitegromab is progressing, with a decision anticipated mid-2026.

The company received a Complete Response Letter in September 2025 related to observations at Catalent Indiana, which did not cite other approvability concerns.

Full analysis

Scholar Rock's resubmission of its Biologics License Application for apitegromab represents a critical step toward potential regulatory approval for its lead candidate in spinal muscular atrophy. The company has aligned with the FDA on including both the Catalent Indiana facility and a second fill-finish facility in the resubmission, addressing previous observations from a Complete Response Letter received in September 2025. The anticipated timeline suggests a PDUFA action date in late September 2026, providing investors with a clear regulatory milestone. Concurrent progress with the European Medicines Agency review, with a decision expected mid-2026, indicates potential near-term commercialization opportunities in multiple markets. The company's ability to navigate the regulatory process following the CRL and maintain alignment with the FDA on remediation and submission strategy demonstrates progress in addressing previous manufacturing concerns.

SRRK · Scholar Rock Holding Corporation

Summary

Key takeaways

Full analysis